Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alcon Provides Documents In Philadelphia PBM Investigation

Executive Summary

PBM switch campaigns for ophthalmic drugs may be an area of interest in the federal investigation of pharmaceutical benefit management practices.

You may also be interested in...



Allergan Acular Generic Defense Subject Of FTC Investigation, Apotex Lawsuit

Allergan's exclusivity defense for Acular (ketorolac ophthalmic solution) is the subject of a Federal Trade Commission investigation

Allergan Acular Generic Defense Subject Of FTC Investigation, Apotex Lawsuit

Allergan's exclusivity defense for Acular (ketorolac ophthalmic solution) is the subject of a Federal Trade Commission investigation

ADR Cases Could Be Prosecuted Under Kickback Statute – U.S. Atty Sheehan

The federal anti-kickback statute is broad enough to allow prosecution of pharmaceutical manufacturers for inadequate reporting of adverse events, Philadelphia Assistant U.S. Attorney James Sheehan maintained during a Food & Drug Law Institute meeting Sept. 12 in Washington, D.C

Related Content

UsernamePublicRestriction

Register

PS038725

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel